Amyloid Beta 1-42 Oligomer Antibody: ATTO 594

Our amyloid beta oligomer antibody has been tested for specificity against AB 1-42 aggregates, with higher specificity to oligomers demonstrated. In the brain, amyloid beta peptide (Aβ) is generated by protease cleavage of amyloid precursor protein (APP), which aggregates into oligomers, protofibrils, fibrils and ultimately plaques in neurodegenerative diseases. The accumulation of Aβ plaques in the brain is considered a hallmark of Alzheimer’s disease (AD), and most of the drugs tested for AD in the past 20 years have targeted amyloid beta accumulation (1). The immunogen used was our Amyloid Beta 1-42 (Aβ42) Oligomers are generated from Amyloid Beta Peptide 1-42 pre-treated with 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) as previously published (2,3).

A 1:4000 dilution of SMC-618 was sufficient for detection of 2ng of AB 1-42 oligomers by dot blot analysis with goat-anti-rabbit:HRP as the secondary and by self-sandwich ELISA analysis (capture at 1 ug/mL, detection at 0.2 ug/mL).

1. Panza et al. 2019. Nat Rev Neurol. 15:73-88 https://doi.org/10.1038/s41582-018-0116-6 2. Stine et al. 2003. JBC. 278(13):11612-22. doi: 10.1074/jbc.M210207200 3. Ahmed et al. 2010. Nature Structural & Molecular Biology. 17(5):561 doi: 10.1038/nsmb.1799